LabGenius Appoints Dr. Gino Van Heeke As Chief Scientific Officer
With over 20 years of industry experience, the former Senior Director, Discovery and Early Development at Ablynx, will lead LabGenius’ drug discovery and pre-clinical development activities.
LabGenius, the machine learning (ML)-driven protein engineering company, announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO). In this role, Gino will leverage his wealth of drug discovery and development experience to direct LabGenius’ scientific strategy.
Recommended AI News: Top 5 NFT Collectibles Worth $10.2 Billion in November
“I’m extremely pleased to welcome Gino to the company as CSO,” said Dr. James Field, Founder and CEO of LabGenius. “Gino is an accomplished scientific leader with an impressive track record of successfully advancing drug candidates into pre-clinical and clinical development.”
Gino joins LabGenius from Engitix Therapeutics, where, as CSO, he established a portfolio of projects and initiated the company’s first drug discovery campaign. Before this, Gino was Senior Director, Discovery and Early Development at Ablynx where he led the discovery of NANOBODY® drug candidates and their transition to clinical development. Prior to his move into biotech, Gino held several senior positions at Novartis Institutes for Biomedical Research over a 22-year tenure, including Executive Director for Biologics.
Recommended AI News: Confluence Announces Partnership With Fund Service Provider, FundHero
Speaking about his appointment, Dr. Gino Van Heeke said, “The ML-driven protein engineering platform that the team at LabGenius has expertly built presents a tremendous opportunity to revolutionize the way in which drugs are discovered. With solid foundations in place, I am delighted to join the company and apply my drug discovery knowledge and experience to ensure we use our unique platform in the most effective way possible.”
Dr. Edwin Moses, LabGenius Chairman commented “Gino’s expertise in translational research, coupled with LabGenius’ ML-driven drug discovery platform, is an excellent combination which I believe will further accelerate the company’s successful development.”
Recommended AI News: Instamojo Brings Seamless Logistics For Small Businesses With Five Key Partnerships For Delivery
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.